{"success":true,"data":{"pressRelease":{"id":"161266","rtpr_id":"nPrec9g0a-20261006","ticker":"NWBO","exchange":"OTC","all_tickers":["NWBO"],"title":"Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference","author":"PR Newswire","published_at":"2026-10-06T07:00:02.165Z","article_body":"Northwest Biotherapeutics Announces Keynote Presentation on Harnessing\nImmunity: A Personalized, Multi-Target Approach to Cancer At the UK National\nHealth Service Annual Oncology Conference\nPR Newswire\n\nBETHESDA, Md., Oct. 6, 2026\n\nBETHESDA, Md., Oct. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics\n(OTCQB:NWBO) (the \"Company\" or \"NWBio\"), a biotechnology company developing\nDCVax® personalized immune therapies for solid tumor cancers, announced that\nDr. Marnix Bosch, the Company's Chief Technical Officer, will be making an\ninvited keynote presentation entitled \"Harnessing Immunity: A Personalised,\nMulti-Target Approach to Cancer\" at the annual UK National Health Service\n(NHS) CancerCare Oncology Conference on Tuesday, October 6, at 11:30 a.m. UK\ntime.\n\n\nThe CancerCare Conference brings together NHS leaders and clinicians, cancer\nalliances and other healthcare professionals from across the UK to discuss\ndevelopments in cancer care, innovation and emerging treatments.\n\nDr. Bosch will discuss the new era of cancer vaccines, the need for\npersonalized treatments, the unique capabilities of dendritic cell (DC) based\ncancer vaccines such as DCVax®, clinical trial results, potential combination\ntreatments and related matters. The slide deck will be posted on the\nNorthwest Biotherapeutics website after the NHS conference.\n\nAbout Northwest Biotherapeutics\n\nNorthwest Biotherapeutics is a biotechnology company focused on developing\npersonalized immunotherapy products that are designed to treat cancers more\neffectively than current treatments, without toxicities of the kind associated\nwith chemotherapies, and on a cost-effective basis.  The Company has a broad\nplatform technology for DCVax(®) dendritic cell-based vaccines. The\nCompany's lead program involves DCVax(®)-L treatment for glioblastoma (GBM).\n GBM is the most aggressive and lethal form of primary brain cancer, and is\nan \"orphan disease.\"  The Company has completed a 331-patient Phase III\ntrial of DCVax-L for GBM, presented the results in scientific meetings,\npublished the results in JAMA Oncology and submitted a MAA for commercial\napproval in the UK.  The MAA is currently undergoing review.  The Company\nhas also developed DCVax(®)-Direct for inoperable solid tumor cancers.  It\nhas completed a 40-patient Phase I trial and plans to pursue Phase II trials\nthis year. The Company previously conducted a Phase I/II trial with DCVax-L\nfor advanced ovarian cancer together with the University of Pennsylvania.\n\nDisclaimer\n\nStatements made in this news release that are not historical facts, including\nstatements concerning plans for DCVax(®) are forward-looking statements\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nWords such as \"expect,\" \"believe,\" \"intend,\" \"design,\" \"plan,\" \"continue,\"\n\"may,\" \"will,\" \"anticipate,\" and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these identifying words. Actual results may differ materially from\nthose projected in any forward-looking statement. Readers should not rely upon\nforward-looking statements. There are a number of important factors that could\ncause actual results to differ materially from those anticipated, including,\nwithout limitation, risks related to delays or uncertainties in regulatory\nprocesses and decisions, risks related to the Company's ability to achieve\ntimely performance of third parties, risks related to whether the Company's\nproducts will be viewed as demonstrating safety and efficacy, risks related to\nthe Company's ongoing ability to raise additional capital, and other risks\nincluded in the Company's Securities and Exchange Commission (\"SEC\") filings.\nAdditional information on the foregoing risk factors and other factors,\nincluding Risk Factors, which could affect the Company's results, is included\nin its SEC filings. Finally, there may be other factors not mentioned above or\nincluded in the Company's SEC filings that may cause actual plans, results or\ntimelines to differ materially from those projected in any forward-looking\nstatement. The Company assumes no obligation to update any forward-looking\nstatements as a result of new information, future events or developments,\nexcept as required by securities laws.\n\nCONTACTS\n\nNorthwest Biotherapeutics\n\nDave Innes\n804-513-4758\ndinnes@nwbio.com\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/northwest-biotherapeutics-announces-keynote-presentation-on-harnessing-immunity-a-personalized-multi-target-approach-to-cancer-at-the-uk-national-health-service-annual-oncology-conference-302899178.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS262739/NORTHWEST-BIOTHERAPEUTICS_-INC_-LOGO.jpg?id=OA2989176\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPrec9g0a-20261006","title":"Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference","author":"PR Newswire","ticker":"NWBO","created":"2026-10-06T07:00:02.165Z","tickers":["NWBO"],"exchange":"OTC","article_body":"Northwest Biotherapeutics Announces Keynote Presentation on Harnessing\nImmunity: A Personalized, Multi-Target Approach to Cancer At the UK National\nHealth Service Annual Oncology Conference\nPR Newswire\n\nBETHESDA, Md., Oct. 6, 2026\n\nBETHESDA, Md., Oct. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics\n(OTCQB:NWBO) (the \"Company\" or \"NWBio\"), a biotechnology company developing\nDCVax® personalized immune therapies for solid tumor cancers, announced that\nDr. Marnix Bosch, the Company's Chief Technical Officer, will be making an\ninvited keynote presentation entitled \"Harnessing Immunity: A Personalised,\nMulti-Target Approach to Cancer\" at the annual UK National Health Service\n(NHS) CancerCare Oncology Conference on Tuesday, October 6, at 11:30 a.m. UK\ntime.\n\n\nThe CancerCare Conference brings together NHS leaders and clinicians, cancer\nalliances and other healthcare professionals from across the UK to discuss\ndevelopments in cancer care, innovation and emerging treatments.\n\nDr. Bosch will discuss the new era of cancer vaccines, the need for\npersonalized treatments, the unique capabilities of dendritic cell (DC) based\ncancer vaccines such as DCVax®, clinical trial results, potential combination\ntreatments and related matters. The slide deck will be posted on the\nNorthwest Biotherapeutics website after the NHS conference.\n\nAbout Northwest Biotherapeutics\n\nNorthwest Biotherapeutics is a biotechnology company focused on developing\npersonalized immunotherapy products that are designed to treat cancers more\neffectively than current treatments, without toxicities of the kind associated\nwith chemotherapies, and on a cost-effective basis.  The Company has a broad\nplatform technology for DCVax(®) dendritic cell-based vaccines. The\nCompany's lead program involves DCVax(®)-L treatment for glioblastoma (GBM).\n GBM is the most aggressive and lethal form of primary brain cancer, and is\nan \"orphan disease.\"  The Company has completed a 331-patient Phase III\ntrial of DCVax-L for GBM, presented the results in scientific meetings,\npublished the results in JAMA Oncology and submitted a MAA for commercial\napproval in the UK.  The MAA is currently undergoing review.  The Company\nhas also developed DCVax(®)-Direct for inoperable solid tumor cancers.  It\nhas completed a 40-patient Phase I trial and plans to pursue Phase II trials\nthis year. The Company previously conducted a Phase I/II trial with DCVax-L\nfor advanced ovarian cancer together with the University of Pennsylvania.\n\nDisclaimer\n\nStatements made in this news release that are not historical facts, including\nstatements concerning plans for DCVax(®) are forward-looking statements\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nWords such as \"expect,\" \"believe,\" \"intend,\" \"design,\" \"plan,\" \"continue,\"\n\"may,\" \"will,\" \"anticipate,\" and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these identifying words. Actual results may differ materially from\nthose projected in any forward-looking statement. Readers should not rely upon\nforward-looking statements. There are a number of important factors that could\ncause actual results to differ materially from those anticipated, including,\nwithout limitation, risks related to delays or uncertainties in regulatory\nprocesses and decisions, risks related to the Company's ability to achieve\ntimely performance of third parties, risks related to whether the Company's\nproducts will be viewed as demonstrating safety and efficacy, risks related to\nthe Company's ongoing ability to raise additional capital, and other risks\nincluded in the Company's Securities and Exchange Commission (\"SEC\") filings.\nAdditional information on the foregoing risk factors and other factors,\nincluding Risk Factors, which could affect the Company's results, is included\nin its SEC filings. Finally, there may be other factors not mentioned above or\nincluded in the Company's SEC filings that may cause actual plans, results or\ntimelines to differ materially from those projected in any forward-looking\nstatement. The Company assumes no obligation to update any forward-looking\nstatements as a result of new information, future events or developments,\nexcept as required by securities laws.\n\nCONTACTS\n\nNorthwest Biotherapeutics\n\nDave Innes\n804-513-4758\ndinnes@nwbio.com\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/northwest-biotherapeutics-announces-keynote-presentation-on-harnessing-immunity-a-personalized-multi-target-approach-to-cancer-at-the-uk-national-health-service-annual-oncology-conference-302899178.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS262739/NORTHWEST-BIOTHERAPEUTICS_-INC_-LOGO.jpg?id=OA2989176\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-06T07:00:02.222958542Z","server_sent_at_ms":1791270002222},"received_at":"2026-10-06T07:00:02.272Z","source_url":null},"analysis":{"id":"149804","press_release_id":"161266","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will deliver an invited keynote at the UK NHS CancerCare Oncology Conference on October 6.\n\nThe talk covers the new era of cancer vaccines and the company's DCVax platform, including clinical trial results and potential combination treatments; slides will be posted to the company website afterward.\n\nThe event is promotional rather than data-generating: the company's UK MAA for DCVax-L in glioblastoma remains under review, and no new results or regulatory milestones were announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Conference keynote spotlighting DCVax platform ahead of pending UK MAA review -- visibility event, no new data."},"keyFigures":{"customDimensions":{"dcvax_l_phase3_patients":331,"dcvax_direct_phase1_patients":40}},"namedEntities":{"people":[{"name":"Dr. Marnix Bosch","role":"Chief Technical Officer"},{"name":"Dave Innes","role":"media contact"}],"products":["DCVax-L","DCVax-Direct"],"companies":[{"name":"Northwest Biotherapeutics","ticker":"NWBO","relationship":"filer"},{"name":"UK National Health Service (NHS)","relationship":"conference host"},{"name":"University of Pennsylvania","relationship":"prior trial collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"An invited keynote presentation at an NHS oncology conference is a visibility/awareness event with no new data, regulatory decision, or financial impact disclosed."},"tickerRelevance":{"others":[],"primary":"NWBO"},"globalImportance":12,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-presentation","issuerAuthored":true,"newDataDisclosed":false}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will deliver an invited keynote at the UK NHS CancerCare Oncology Conference on October 6.\n\nThe talk covers the new era of cancer vaccines and the company's DCVax platform, including clinical trial results and potential combination treatments; slides will be posted to the company website afterward.\n\nThe event is promotional rather than data-generating: the company's UK MAA for DCVax-L in glioblastoma remains under review, and no new results or regulatory milestones were announced.","key_figures":{"customDimensions":{"dcvax_l_phase3_patients":331,"dcvax_direct_phase1_patients":40}},"named_entities":{"people":[{"name":"Dr. Marnix Bosch","role":"Chief Technical Officer"},{"name":"Dave Innes","role":"media contact"}],"products":["DCVax-L","DCVax-Direct"],"companies":[{"name":"Northwest Biotherapeutics","ticker":"NWBO","relationship":"filer"},{"name":"UK National Health Service (NHS)","relationship":"conference host"},{"name":"University of Pennsylvania","relationship":"prior trial collaborator"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T07:00:06.750Z","global_importance":12,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-presentation","issuerAuthored":true,"newDataDisclosed":false}},"durationMs":4453,"modelName":"glm-5.3-flashx"}}